CN104684553A - 治疗多发性硬化症的组合疗法 - Google Patents

治疗多发性硬化症的组合疗法 Download PDF

Info

Publication number
CN104684553A
CN104684553A CN201380052107.4A CN201380052107A CN104684553A CN 104684553 A CN104684553 A CN 104684553A CN 201380052107 A CN201380052107 A CN 201380052107A CN 104684553 A CN104684553 A CN 104684553A
Authority
CN
China
Prior art keywords
dimethyl fumarate
teriflunomide
fingolimod
laquinimod
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380052107.4A
Other languages
English (en)
Chinese (zh)
Inventor
T.特韦
R.鲁普
P.M.安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forward Pharma AS
Original Assignee
Forward Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forward Pharma AS filed Critical Forward Pharma AS
Priority to CN201710423062.7A priority Critical patent/CN107669668A/zh
Priority to CN202110575106.4A priority patent/CN113288891A/zh
Publication of CN104684553A publication Critical patent/CN104684553A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201380052107.4A 2012-08-03 2013-08-02 治疗多发性硬化症的组合疗法 Pending CN104684553A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201710423062.7A CN107669668A (zh) 2012-08-03 2013-08-02 治疗多发性硬化症的组合疗法
CN202110575106.4A CN113288891A (zh) 2012-08-03 2013-08-02 治疗多发性硬化症的组合疗法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP12179232.9 2012-08-03
EP12179232.9A EP2692343A1 (en) 2012-08-03 2012-08-03 Combination therapy for treatment of multiple sclerosis
US201261712008P 2012-10-10 2012-10-10
EP12187939.9 2012-10-10
US61/712008 2012-10-10
EP12187939.9A EP2692344A1 (en) 2012-08-03 2012-10-10 Combination therapy for treatment of Multiple sclerosis
PCT/EP2013/066285 WO2014020156A1 (en) 2012-08-03 2013-08-02 Combination therapy for treatment of multiple sclerosis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202110575106.4A Division CN113288891A (zh) 2012-08-03 2013-08-02 治疗多发性硬化症的组合疗法
CN201710423062.7A Division CN107669668A (zh) 2012-08-03 2013-08-02 治疗多发性硬化症的组合疗法

Publications (1)

Publication Number Publication Date
CN104684553A true CN104684553A (zh) 2015-06-03

Family

ID=47008405

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380052107.4A Pending CN104684553A (zh) 2012-08-03 2013-08-02 治疗多发性硬化症的组合疗法
CN202110575106.4A Pending CN113288891A (zh) 2012-08-03 2013-08-02 治疗多发性硬化症的组合疗法
CN201710423062.7A Pending CN107669668A (zh) 2012-08-03 2013-08-02 治疗多发性硬化症的组合疗法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110575106.4A Pending CN113288891A (zh) 2012-08-03 2013-08-02 治疗多发性硬化症的组合疗法
CN201710423062.7A Pending CN107669668A (zh) 2012-08-03 2013-08-02 治疗多发性硬化症的组合疗法

Country Status (20)

Country Link
US (2) US20150164849A1 (enExample)
EP (4) EP2692343A1 (enExample)
JP (2) JP2015523407A (enExample)
KR (3) KR20210147083A (enExample)
CN (3) CN104684553A (enExample)
AU (3) AU2013298517A1 (enExample)
CA (2) CA2880742C (enExample)
DK (1) DK2879672T3 (enExample)
EA (1) EA201590166A8 (enExample)
ES (1) ES2674947T3 (enExample)
HR (1) HRP20180939T1 (enExample)
HU (1) HUE038382T2 (enExample)
LT (1) LT2879672T (enExample)
PL (1) PL2879672T3 (enExample)
PT (1) PT2879672T (enExample)
RS (1) RS57567B1 (enExample)
SI (1) SI2879672T1 (enExample)
SM (1) SMT201800380T1 (enExample)
TR (1) TR201808859T4 (enExample)
WO (1) WO2014020156A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110381942A (zh) * 2017-03-14 2019-10-25 埃科特莱茵药品有限公司 包含珀奈莫德的药物组合
CN114401742A (zh) * 2019-09-11 2022-04-26 诺华股份有限公司 通过转换疗法治疗rms
US12338290B2 (en) 2016-08-15 2025-06-24 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334378B1 (en) 2008-08-19 2014-04-09 XenoPort, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
UA122064C2 (uk) 2014-12-11 2020-09-10 Актеліон Фармасьютікалз Лтд Схема дозування для селективного агоніста рецептора s1p1
MA41139A (fr) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
TR201820976A2 (tr) * 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
EP4117785A4 (en) 2020-03-13 2024-04-17 Marc J. Simard METHODS OF TREATMENT OF MULTIPLE SCLEROSIS
CA3181368A1 (en) * 2020-05-06 2021-07-29 Imcyse Sa Peptides and methods for the treatment of multiple sclerosis
CN116672325B (zh) * 2023-06-06 2024-09-03 哈尔滨工业大学 一种包覆中性粒细胞膜的聚芬戈莫德纳米前药的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011100589A1 (en) * 2010-02-12 2011-08-18 Biogen Idec Ma Inc. Neuroprotection in demyelinating diseases
CN102369001A (zh) * 2009-01-09 2012-03-07 前进制药公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006307A2 (en) 2005-07-07 2007-01-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369001A (zh) * 2009-01-09 2012-03-07 前进制药公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
WO2011100589A1 (en) * 2010-02-12 2011-08-18 Biogen Idec Ma Inc. Neuroprotection in demyelinating diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERND C. KIESEIER, ET AL.: "The future of multiple sclerosis therapy", 《PHARMACOLOGICAL RESEARCH》 *
DEVON CONWAY, ET AL.: "Combination therapy in multiple sclerosis", 《LANCET NEUROLOGY》 *
JAI PERUMAL, ET AL.: "Emerging Disease-Modifying Therapies in Multiple Sclerosis", 《CURRENT TREATMENT OPTIONS IN NEUROLOGY》 *
JEFFREY A. ET AL.: "The future of multiple sclerosis treatment", 《JOURNAL OF THE NEUROLOGICAL SCIENCES 》 *
OSCAR FERNÁNDEZ: "Combination therapy in multiple sclerosis", 《JOURNAL OF THE NEUROLOGICAL SCIENCES》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12338290B2 (en) 2016-08-15 2025-06-24 Novartis Ag Regimens and methods of treating multiple sclerosis using ofatumumab
CN110381942A (zh) * 2017-03-14 2019-10-25 埃科特莱茵药品有限公司 包含珀奈莫德的药物组合
CN110381942B (zh) * 2017-03-14 2022-12-27 埃科特莱茵药品有限公司 包含珀奈莫德的药物组合
US11723896B2 (en) 2017-03-14 2023-08-15 Actelion Pharmaceuticals Ltd Pharmaceutical combination comprising ponesimod
CN114401742A (zh) * 2019-09-11 2022-04-26 诺华股份有限公司 通过转换疗法治疗rms
CN114401742B (zh) * 2019-09-11 2024-05-24 诺华股份有限公司 通过转换疗法治疗rms

Also Published As

Publication number Publication date
CA2880742A1 (en) 2014-02-06
DK2879672T3 (en) 2018-07-30
EA201590166A1 (ru) 2015-06-30
KR20150040338A (ko) 2015-04-14
KR20210147083A (ko) 2021-12-06
PL2879672T3 (pl) 2018-10-31
CA3107367A1 (en) 2014-02-06
EP2879672B1 (en) 2018-04-11
US20150164849A1 (en) 2015-06-18
EP3398595A1 (en) 2018-11-07
LT2879672T (lt) 2018-07-10
HK1211210A1 (en) 2016-05-20
CN113288891A (zh) 2021-08-24
CN107669668A (zh) 2018-02-09
HRP20180939T1 (hr) 2018-12-14
JP2015523407A (ja) 2015-08-13
AU2020201290A1 (en) 2020-03-12
AU2018201801B2 (en) 2019-11-21
HUE038382T2 (hu) 2018-10-29
EP2692343A1 (en) 2014-02-05
JP2018150375A (ja) 2018-09-27
AU2020201290B2 (en) 2021-08-19
SI2879672T1 (sl) 2018-10-30
US20190091190A1 (en) 2019-03-28
SMT201800380T1 (it) 2018-09-13
WO2014020156A1 (en) 2014-02-06
TR201808859T4 (tr) 2018-07-23
AU2018201801A1 (en) 2018-04-05
CA2880742C (en) 2021-03-16
EA201590166A8 (ru) 2015-10-30
ES2674947T3 (es) 2018-07-05
EP2879672A1 (en) 2015-06-10
AU2013298517A1 (en) 2015-03-05
KR20200142597A (ko) 2020-12-22
EP2692344A1 (en) 2014-02-05
PT2879672T (pt) 2018-07-03
RS57567B1 (sr) 2018-10-31

Similar Documents

Publication Publication Date Title
CA2880742C (en) Combination therapy for treatment of multiple sclerosis
Feagan et al. 943b Induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial
WO2009155475A1 (en) Paediatric compositions for treating1 multiple sclerosis
WO2007000764A2 (en) Compositions and methods for enhancement of sexual function
JP6884841B2 (ja) 多発性硬化症を処置するための併用療法
HK1211210B (en) Combination therapy for treatment of multiple sclerosis
WO2024104290A1 (en) Method for treating multiple sclerosis
CA3100635A1 (en) Combinations comprising tropifexor and cenicriviroc
UA127031C2 (uk) Комбінована терапія для лікування розсіяного склерозу
AU2005283829A1 (en) Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder
RU2024108530A (ru) Lou064 для лечения рассеянного склероза
EP1758563A1 (en) Combination therapy with glatiramer acetate and minocycline for the treatment of multiple sclerosis
AU2019201291A1 (en) Paediatric compositions for treating multiple sclerosis
WO2012110946A1 (en) Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150603

WD01 Invention patent application deemed withdrawn after publication